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Genetic differences between humans and in vivo
model systems, including mice and nonhuman pri-
mates, make it difficult to predict the efficacy
of immunoglobulin G (IgG) activity in humans and
understand the molecular and cellular mechanisms
underlying that activity. To bridge this gap, we estab-
lished a small-animal model system that allowed us
to study human IgG effector functions in the context
of an intact human immune system without the
interference of murine Fcg receptors expressed on
mouse innate immune effector cells in vivo. Using a
model of B cell depletion with different human IgG
variants that recognize CD20, we show that this hu-
manized mouse model can provide unique insights
into the mechanism of human IgG activity in vivo.
Importantly, these studies identify the bone marrow
as a niche with low therapeutic IgG activity.INTRODUCTION
The therapeutic success of immunoglobulin G (IgG) antibodies
such as rituximab (a chimeric CD20-specific IgG1 antibody)
and herceptin (a her2/neu-specific IgG1 antibody) in the treat-
ment of human cancer and autoimmune disease has fueled in-
terest in the widespread development of IgG-based biologicals
(Carter, 2006; St Clair, 2009; Waldmann, 2003; Weiner et al.,
2010). Animal model systems frequently used for the preclinical
evaluation of IgG activity and safety include mice, rats, and a
variety of nonhuman primate species. Because they provide
the possibility to delete genes of choice, mouse in vivo model
systems are widely used, and many of our current models of
IgG activity stem from data obtained in mice. Indeed, such
studies have provided valuable insights into the mechanism
of IgG activity, such as the importance of cellular Fcg receptors
(FcgR) for IgG activity and the role of individual FcgRs in IgG
subclass activity in vivo (Beers et al., 2008; Hogarth, 2002;236 Cell Reports 7, 236–248, April 10, 2014 ª2014 The AuthorsNimmerjahn and Ravetch, 2008; Takai, 2002). The relevance
of these basic studies to the human system is supported by
data showing that cancer patients respond better to anticancer
antibodies if they express allelic variants of FcgRs that confer
enhanced binding to the IgG subclass of the therapeutic anti-
body (Cartron et al., 2002; Musolino et al., 2008; Weng et al.,
2004; Weng and Levy, 2003). Despite the similarities between
mice and humans, however, there are several important differ-
ences, such as the cell-type-specific expression pattern of
certain FcgRs and the capacity of some mouse FcgRs to
interact with other Ig isotypes, which are not reflected in
humans (Hirano et al., 2007; Lux and Nimmerjahn, 2013;
Mancardi et al., 2008; Nimmerjahn et al., 2010; Biburger and
Nimmerjahn, 2012). As mentioned in previous studies, allelic
variants of the low-affinity FcgRs FcgRIIB, FcgRIIA, and
FcgRIIIA are present in the human population that can impact
either the affinity or functionality of these receptors (Baeren-
waldt et al., 2011; Bruhns et al., 2009; Lux et al., 2013; Smith
and Clatworthy, 2010). Moreover, certain human FcgRs, such
as the neutrophil-specific FcgRIIIB, are not present in mice at
all. Thus, several factors that potentially influence IgG activity
in humans are not recapitulated in any of the currently available
animal models, including nonhuman primates. To combine the
advantages of a small-animal model with the possibility to
study the human immune system in vivo, we used the Rag2/
Il2rg-deficient mouse strain (Rag2/gc/), in which a functional
human immune system can develop upon injection with purified
human hematopoietic stem cells (HSCs) due to the absence of
mouse B cells, T cells, and functional natural killer (NK) cells
(Legrand et al., 2008; Shultz et al., 2012;Traggiai et al., 2004;
Legrand et al., 2009). Although these mice are an excellent
model system for studying the development of the human im-
mune system, they may not be the optimal system for studying
human IgG activity in vivo. This is due to the presence of mouse
monocytes, macrophages, and neutrophils expressing high
levels of mouse activating FcgRs, which have the capacity
to interact with human IgG1 antibodies (Lux and Nimmerjahn,
2013). Further complicating the situation, the absence of
mouse B cells and mouse serum antibodies will result in a
high capacity of the mouse high-affinity FcgRI, which is usually
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Figure 1. Generation and Characterization
of Rag2/gc/FcRg Knockout Mice
(A and B) Residual platelet counts in the peripheral
blood of FcRg-, C57BL/6, FcgRI/, and
FcgRIV/mice (A) or Rag2/gc/ and Rag2/gc/
FcRg/mice (B) upon injection of the humanized
antiplatelet 6A6-hIgG1 antibody.
(C) Analysis of PBMCs in C57BL/6, Rag2/gc/,
and Rag2/gc/FcRg/ mice by flow cytometry,
identifying mouse T (TCRb), B (B220), neutrophil
(CD11B+ and Ly6G+), and Ly6C+ and Ly6C
(GR-1) monocyte subsets.
(D) Expression of the indicated murine FcgRs on
CD11b+ PBMCs of Rag2/gc/ and Rag2/gc/
FcRg/mice. Bar graphs indicate mean residual
platelet counts ± SD of at least two independent
experiments with three to five mice each. Statisti-
cal analysis was performed byMann-Whitney test.
Asterisks indicate values with a significant differ-
ence; *p < 0.05.occupied with mouse serum IgG2a, to interact with human
IgG1, thereby artificially skewing antibody effector functions
toward this receptor.
Thus, we set out to generate an immunodeficient mouse
model that would accept human HSC grafts without expressing
mouse activating FcgRs. We show that this mouse strain effi-
ciently accepts human HSC grafts, which develop into a human
immune system containing all the major hematopoietic cell line-
ages. By using human CD20-specificmonoclonal antibodies, we
demonstrate that human IgG subclasses have a differential ac-
tivity in vivo and depend critically on the IgG constant fragment.
Moreover, this model system allowed us to identify physiological
niches, such as the bone marrow, in which human IgG activity
might be less effective.Cell Reports 7, 236–2RESULTS
Generation and Characterization of
Rag2/gc/FcRg/ Mice
Although Rag2/gc/mice have allowed
unique insights into human immune sys-
tem development and function to be
obtained, studying human IgG activity in
this and other immunodeficient mouse
strains transplanted with human periph-
eral blood mononuclear cells (PBMCs)
are hampered by the fact that many
human IgGsubclasses, andespecially hu-
man IgG1,which is themost abundant IgG
subclass used in human therapy, can bind
to mouse activating FcgRI and FcgRIV
(Lux and Nimmerjahn, 2013). To test
whether human IgG1 can indeed mediate
its activity via one of these mouse FcgRs
in vivo, we generated a humanized IgG1
variant of the mouse platelet-specific
antibody 6A6 (Nimmerjahn et al., 2005;
Nimmerjahn and Ravetch, 2005). Indeed,6A6-hIgG1 efficiently depleted platelets in C57BL/6 and FcgRI-
deficientmice, but was not able to remove platelets in FcRg-defi-
cient mice lacking all activating FcgRs and in FcgRIV-deficient
animals, consistent with previous studies that demonstrated an
important role for thismouse activating FcgR in IgGactivity in vivo
(Figures 1A and 1B; Nimmerjahn et al., 2005, 2010; Seeling et al.,
2013; Biburger et al., 2011; Mancardi et al., 2011; Otten et al.,
2008; Kasperkiewicz et al., 2012; Syed et al., 2009; Baudino
et al., 2008; Kaneko et al., 2006; Hamaguchi et al., 2006). These
results emphasize that studying human IgG activity in currently
available immunodeficient mouse strains transplanted with hu-
man immunecellswill not allow us to distinguish between effector
functionsmediated bymouse and human innate immune effector
cells unless we can discover transplantation conditions that48, April 10, 2014 ª2014 The Authors 237
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Figure 2. Characterization of Human
Immune System Development in Rag2/gc/
FcRg/ Mice
(A) Identification of human B cells (CD19), T cells
(CD3), monocytes (CD33+CD11c+), dendritic cells
(CD33CD11c+), and NK cells (CD33CD56+) in
the blood, spleen, and bone marrow of humanized
Rag2/gc/FcRg/ mice within the hCD45+ cell
population.
(B) Identification of different B cell developmental
stages in the bone marrow, spleen, and blood of
humanized Rag2/gc/FcRg/mice.
(C) Percentage of pro-, pre-, immature, and
mature B cell subpopulations in the bone marrow
of humanized Rag2/gc/FcRg/ mice within the
human B cell population (hCD45+CD19+).
(D) Quantification of serum IgM and IgG levels
in humanized Rag2/gc/FcRg/ mice 16 weeks
posttransplantation.
(E) Presence of cell-surface-associated IgG on
human B cells (CD19+) and human monocytes
(CD33+) in the blood of humanized Rag2/gc/
FcRg/ mice as detected by flow cytometry.
(F) Presence of the human complement compo-
nent C3 in human serum and in the serum of
humanized Rag2/gc/FcRg/ andC57BL/6mice.
All experiments were done with animals at 12–
16 weeks posttransplantation with human HSCs
and at least nine animals per group. Bar graphs
indicate the mean value ± SD. Horizontal lines
indicate the statistical mean.
See also Figure S1 and Table S1.completely eradicate all mouse hematopoietic cells. Therefore, to
generate an immunodeficient mouse strain that does not express
mouse activating FcgRs, we crossed the Rag2/gc/ mouse
strain, which is known to efficiently accept human hematopoietic
cells, with the FcRg-deficient mouse, thereby creating Rag2/gc/
FcRg/ mice. As shown in Figures 1C and 1D, these animals
lack mouse B and T cells, and do not express mouse activating
FcgRs on innate immune effector cells, such as neutrophils and
monocytes, resulting in abrogated activity of the 6A6-hIgG1 anti-
body (Figure 1B). Thus, upon reconstitution of Rag2/gc/FcRg/
mice with a human immune system, only human innate immune
effector cells will express human activating FcgRs,which allowed
us to exclude the contribution of residual mouse innate immune
effector cells beyond any doubt.
Reconstitution of a Human Immune System in
Rag2/gc/FcRg/ Mice
Next, we established the experimental conditions for reconstitu-
tion of Rag2/gc/FcRg/mice with human HSCs. Irradiation of238 Cell Reports 7, 236–248, April 10, 2014 ª2014 The Authorsnewborn mice with 6 Gy resulted in the
highest level of reconstitution with human
hematopoietic cells in the peripheral
blood of individual mice 12 weeks after
transplantation (Figure S1A). As previ-
ously described for other immunodefi-
cient mouse strains, in addition to the
blood, human cells were abundantly pre-sent in the spleen and bone marrow of the reconstituted animals
(Figure S1B; Table S1; Shultz et al., 2012; Tanaka et al., 2012;
Traggiai et al., 2004). Moreover, the level of reconstitution did
not impact the cell lineages present in these animals, as B
cells, T cells, monocytes, and NK cells could be found at com-
parable levels in mice with a low or high reconstitution level
(Figures S1C and S1D). A more detailed analysis of human cell
types present in the blood, spleen, and bone marrow of trans-
planted animals identified T cells, monocytes, NK cells, and
dendritic cells, as well as B cells in early and late differentia-
tion stages, including pro- (CD34+CD19+CD10+IgM), pre-
(CD34CD19+CD10+IgM), immature (IgM+CD19+CD10+),
and mature (IgM+CD19+CD10) B cells (Figures 2A–2C), in
line with previous reports (Blom and Spits, 2006; Ghia et al.,
1998; Tanaka et al., 2012; Traggiai et al., 2004). Consistent
with the presence of B cells, serum IgM and IgG were present
in the serum of mice, albeit at much lower levels than in human
serum (Figure 2D). However, this amount seemed sufficient to
result in binding to CD33+ myeloid cells, most likely via the
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C
D
68
C
D
45
non-humanized mouse
C
D
66
c
C
D
16
B
 C
D
45
A
B Chuman humanized mouse
0
100
200
300
R
LU
 (x
10
00
)
RANKL (ng/ml)
0 50 100 200
TRAP staining
D
CD68
C
D
33
human humanized mouse
blood
bone m
arrow
0%
0,1%
0%
1,5%
Figure 3. Presence of Human Macrophage and Neutrophil Populations in Humanized Mice
(A) Immunofluorescence analysis of spleen sections of humans, humanized mice, and nonhumanized mice stained with CD68 to identify macrophages and
CD66c in combination with CD16B to identify neutrophils. CD45 was used to identify human hematopoietic cells.
(B) Cultures of human PBMCs or bone marrow cells of humanized mice in the presence of M-CSF and RANKL to initiate osteoclast development. The purple
staining identifies the osteoclast-associated enzyme TRAP.
(legend continued on next page)
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high-affinity FcgRI expressed on this cell type (Figures 2E and
4A). In contrast to the presence of all essential cell types impor-
tant for IgG-dependent effector functions, these mice did not
produce significant levels of human complement, consistent
with the important role of nonhematopoietic tissues, such as
the liver, for the generation of complement proteins (Figure 2F).
Furthermore, CD66c/CD16B+ neutrophils and CD68+ macro-
phages were abundantly present in the spleen of humanized
mice, as demonstrated previously in other humanized immuno-
deficient mouse strains (Figure 3A; Tanaka et al., 2012). Since
others have demonstrated that these human macrophages are
functional with respect to cytokine secretion and phagocytic
function (Tanaka et al., 2012), we turned our attention to another
bone resident macrophage population, namely, osteoclasts,
which had not previously been investigated in humanized
mice. First, we cultured bone marrow of humanized mice and
human PBMCs with macrophage colony-stimulating factor
(M-CSF) and receptor activator of NF-kB ligand (RANKL), which
drives monocyte precursors into the osteoclast lineage (Naka-
shima et al., 2012). As shown in Figure 3B, this indeed resulted
in the generation of mature osteoclasts, identified by large
multinucleated cells expressing the osteoclast marker tartrate-
resistant acid phosphatase (TRAP). More importantly, these os-
teoclasts were fully functional, as demonstrated by their capacity
to resorb bone matrix (Figure 3C). In contrast to the presence of
human macrophages in the spleen, no CD68-expressing cells
were detectable in the bonemarrow and blood of the humanized
mice and humans (Figure 3D).
A prerequisite for studying human IgG-dependent effector
functions in humanized mice is the presence of human FcgRs
on innate immune effector cells. In humans, FcgRIIIA is the
only activating FcgR expressed onNK cells, whereasmonocytes
and macrophages express a broader repertoire of activating
FcgRs (Hogarth, 2002; Ravetch and Nimmerjahn, 2008). As
shown in Figure 4A, NK cells expressing FcgRIIIA and mono-
cytes positive for FcgRIA, FcgRIIA, FcgRIIB, and FcgRIIIA
were present in the blood, spleen, and bone marrow of these
animals. In combination with FcgRIIIB expression on human
neutrophils (Figure 3A), this suggests that all relevant human
FcgRs are expressed on innate immune effector cells. This
cell-type-specific pattern of FcgR expression was consistent
with the presence of these receptors on CD33+ monocytes in
the respective human organs (Figure 4B), suggesting that human
FcgR expression is fully recapitulated in the humanized Rag2/
gc/FcRg/mice. In a notable exception, there was a low level
of FcgRIIB expression on monocytes in the peripheral blood of
humanized mice, whereas their counterparts in the human blood
were mostly negative for this receptor.
Activity of Human CD20-Specific IgG Subclasses in
Humanized Mice
Because CD20 is the major target for therapeutic B cell-
depleting antibodies, we next assessed the CD20 expression(C) Assessment of the capacity of osteoclasts generated from the bonemarrow of
RANKL to resorb bone matrix.
(D) Analysis of humanized mouse or human blood and bone marrow to detect C
posttransplantation with human HSCs and at least two animals per group. Bar g
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humans (Johnson and Press, 2000; Sanz and Lee, 2010). As
shown in Figure 5A, CD20 was highly expressed on all IgM+ B
cell populations in the blood, spleen, and bone marrow of
humanizedmice. In contrast, pro- and pre-B cell populations ex-
pressed only very small amounts of CD20, whereas the majority
of immature B cells were strongly positive for this marker. Of
note, mouse CD20 has been demonstrated to be absent from
pro-B and the vast majority of pre-B cells, and to be expressed
only starting from the very late pre-B to immature B cell stage.
Interestingly, this mouse-specific expression pattern was reca-
pitulated in transgenic mice expressing human CD20, further
emphasizing the need for humanized mouse models to fully
match the human expression pattern especially during early B
cell development (Gong et al., 2005; Uchida et al., 2004b).
As a CD20-specific therapeutic antibody, we chose the hy-
bridoma clone 1F5, which was used in early human clinical trials
to deplete B cells in its mouse IgG2a form, and generated all four
human IgG subclass switch variants of this antibody (Johnson
and Press, 2000). Upon injection of equal amounts of these
IgG switch variants into humanized mice (10 mg per mouse),
we could show that the 1F5-IgG1, 1F5-IgG2, and 1F5-IgG3 var-
iants were more efficient in reducing B cell counts compared
with 1F5-IgG4 (Figures 5B–5D). Importantly, this different level
of activity could not be explained by a different half-life of these
IgG switch variants in humanized mice in vivo (Figure S2A). In a
similar manner, the amount of human cells present in these ani-
mals did not correlate with the level of B cell depletion (Figures
S2B–S2D). Of note, although human IgG4 is widely considered
not to have any cytotoxic activity, it clearly had the capacity to
deplete B cells, which is consistent with recent in vitro studies
demonstrating that especially large IgG4 immune complexes
can indeed bind to FcgRs, such as FcgRI (Bruhns et al., 2009;
Lux and Nimmerjahn, 2011). Overall, the observed differences
in in vivo activity are in line with previous results obtained in clas-
sical mouse models, which demonstrated that the activity of IgG
subclasses in vivo correlates with their affinity for different FcgRs
(Fossati-Jimack et al., 2000; Hamaguchi et al., 2006; Nimmer-
jahn and Ravetch, 2005). With respect to the kinetics of B cell
depletion, the majority of B cells were absent from the peripheral
blood of humanized mice 24 hr after anti-CD20 injection (Fig-
ure 5C). Especially for the IgG1 and IgG2 switch variants, B
cell depletion was long lasting and B cell counts did not return
to normal levels over the observation period of the experiment
(Figure 5D). Similar results have been obtained in murine models
of B cell depletion with CD20-specific antibodies and in human
patient cohorts treated with rituximab (Figure S2E; Hamaguchi
et al., 2006; Sanz et al., 2007; Uchida et al., 2004a; Beers
et al., 2008). Of note, B cell depletion was fully dependent on
the IgG Fc fragment, as neither F(ab0)2 fragments nor deglycosy-
lated variants of the same antibody were able to induce a reduc-
tion in B cell counts (Figures 5E and 5F). These findings support
the notion that despite the capacity of antibodies against CD20humanizedmice in the presence of M-CSF and the indicated concentrations of
D68+ macrophages. All experiments were done with animals at 12–16 weeks
raphs indicate mean value ± SD.
AB
Figure 4. Expression of Human FcgRs on Innate Immune Effector Cells
Expression of the indicated human FcgRs on CD33+ monocytes and CD56+ NK cells in the blood, spleen, and bone marrow of humanized Rag2/gc/FcRg/
mice (A) or humans (B) as determined by flow cytometry. Depicted is a representative result from nine independent animals at 12–16weeks posttransplantation or
a minimum of three independent human samples. Cells from five humanized mice were pooled for staining of FcgR expression on peripheral blood cells.to directly inhibit B cell proliferation and induce apoptosis
without secondary crosslinking in vitro, the IgG Fc fragment is
crucial for anti-CD20-dependent B cell depletion in vivo (Bona-
vida, 2007; Shan et al., 1998).
To determine whether FcgR allelic variants represented in the
HSCs used to reconstitute the mice with a human immune sys-
tem might explain some of the differences in antibody activity
observed between the higher- and lower-responder mice, wegenotyped the donors (Table S2) and color-coded all of the
mice that carried specific FcgRIIA high/low affinity and FcgRIIIA
high/low affinity alleles. As shown in Figures 5C and 5D, this did
not show a clear correlation with the activity of antibody-medi-
ated B cell depletion. Similar results were obtained in human
lymphoma patients before and after treatment with rituximab,
suggesting that B cell depletion is not affected by differences
in FcgR allelic variants, at least at the studied antibodyCell Reports 7, 236–248, April 10, 2014 ª2014 The Authors 241
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Figure 5. Anti-CD20 IgG-Mediated B Cell Depletion in Humanized Mice
(A) Detection of CD20 expression on pro- (CD45+CD19+CD10+CD34+IgM), pre- (CD45+CD19+CD10+CD34IgM), immature (CD45+CD19+CD10+
CD34IgM+), and mature B cells (CD45+CD19+CD10CD34IgM+) in the bone marrow (BM) and on mature B cells in the blood and spleen of humanized mice
and humans via flow cytometry.
(B) Representative example of the differential capacity of the CD20-specific 1F5-IgG1 and 1F5-IgG4 switch variants to deplete B cells (CD19+) in peripheral blood
of humanized mice 24 hr after antibody administration.
(C and D) Groups of humanized mice (n = 11–20) were injected with 10 mg of the indicated 1F5 IgG variant, and B cell depletion in the peripheral blood was
assessed at 1 (C) or 7 (D) days after anti-CD20 injection. The FcgRIIA-131H/R and FcgRIIIA-158F/V genotype of the donors was determined. Low-affinity donors
(legend continued on next page)
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concentration in the blood of humanized mice and humans (Fig-
ure S2E). In addition to the blood, we also investigated the ca-
pacity of the IgG1 switch variant to deplete B cells in the spleen
and bone marrow. As shown in Figures 6A–6C, a single injection
of 1, 10, and 100 mg anti-CD20 IgG1 efficiently depletedmature B
cells in the blood and spleen. In contrast, depletion of mature B
cells in the bone marrow was less efficient and required an at
least 10-fold higher antibody dose (Figure 6D). Even more strik-
ing, although the immature B cells expressed CD20 to a level
comparable to that observed in mature B cells, they never
reached a significant level of depletion. The same applied for
pro- and pre-B cells, although these B cell subsets clearly ex-
pressedmuch lower amounts of this cell-surfacemarker (Figures
5A and 6D). Again, no clear correlation with the allelic variants of
activating FcgRs was notable (Table S3). A possible explanation
for this phenomenon might be a lower availability of the thera-
peutic CD20-specific antibody in the bone marrow. To address
this question experimentally, we injected a fluorescently labeled
aglycosylated version of the CD20-specific antibody to prevent
the rapid depletion of anti-CD20-coated B cells in the blood
and spleen. As shown in Figures 6E and 6F, all mature B cell pop-
ulations were labeled by the injected antibody regardless of their
anatomical localization. In line with the comparable level of CD20
expression, immature B cells displayed the same amount of ther-
apeutic antibody binding as mature B cells. As expected, pro-
and pre-B cells were stained at a lower but still clearly detectable
level. Another reason for this reduced level of B cell depletion
may be the lack of responsible innate immune effector cells.
As shown in Figures 2A and 4A, however, NK cells and CD33+
myeloid cells were present in the bone marrow. A more detailed
analysis of the CD33+ cells in the bone marrow revealed that the
majority of these were negative for c-kit and CD34, and thus
represent more mature CD14 high- and low-monocyte subsets,
as expected (Figure 6G). In contrast to monocytes, CD68+
macrophages were present only in very low amounts in the
bone marrow or virtually absent in the blood from humanized
mice and humans (Figure 3D). To further validate this observa-
tion, we analyzed the efficacy of B cell depletion in the bone
marrow of C57BL/6 mice with an antibody specific for mouse
CD20. Again, the depletion of immature B cells required a
much higher dose, despite a similar binding of the CD20-specific
antibody compared with mature B cells, which were depleted
with a similar efficacy compared with the blood and spleen (Fig-
ure S3), in line with previous reports. In contrast to what was
observed in humans and humanized mice, pro-B and pre-B cells
in C57BL/6 mice did not express CD20, and accordingly could
not be recognized via the CD20-specific antibody (Figure S3B).
Therefore, it was not possible to assess their depletion, providing
yet another argument for the necessity of a humanized mouse
model.(HR-FF, RR-FF, and RR-FV) are depicted in red, medium-affinity donors (HR-FV)
shown in green.
(E) Groups of humanized mice were injected with intact anti-CD20 IgG1 or an ant
injection.
(F) Peripheral blood B cell counts in humanized mice 24 hr after injection of PBS,
performed by Kruskal-Wallis test and subsequent post hoc tests. Asterisks indic
See also Figure S2 and Table S2.DISCUSSION
Taken together, our results provide evidence that Rag2/gc/
FcRg/ mice might be a valuable tool for studying human
IgG activity in a preclinical setting in vivo. Compared with inject-
ing human PBMCs into immunodeficient Rag2/gc/, NOD/
SCID, or NOD/SCID/gc/ mice, which are frequently used as
surrogate humanized mouse models to study human IgG activ-
ity, this mouse model has several advantages (Goldman et al.,
1998; Ito et al., 2002). Most importantly, mouse innate immune
effector cells in Rag2/gc/FcRg/ mice no longer have func-
tional activating FcgRs, which allowed us to study the interaction
of human antibodies with human target and effector cells in vivo.
Our work reveals that human IgG4 antibodies are able to deplete
target cells, and is fully consistent with recent in vitro studies
(Bruhns et al., 2009; Lux et al., 2013). Moreover, the presence
of B cells in all developmental stages expressing physiological
levels of the target antigen in all relevant organ structures and
niches is not reflected in the NOD/SCID model system reconsti-
tuted with human PBMCs in the peritoneum. Similar arguments
apply to transgenic mouse models that express human B cell
antigens, such as human CD19 and CD20, on mouse B cells
(but lack human innate immune effector cells), and to mice that
are transgenic for all human FcgRs, in which human serum anti-
bodies and the target human antigen are not present (Beers
et al., 2008; Gong et al., 2005; Yazawa et al., 2005; Smith
et al., 2012). Of note, the expression pattern of human CD20
on early mouse B cell progenitors in the bone marrow of human
CD20 transgenic mice seems to mimic the expression pattern of
mouse CD20, being virtually absent from pro-B and pre-B cell
stages (Gong et al., 2005; Uchida et al., 2004b). In contrast,
the expression of human CD20 in humanized Rag2/gc/FcRg/
mice fully resembled the human expression pattern. Another
attractive feature is the long-term reconstitution with human
immune cells, which may allow the activity of therapeutic anti-
bodies to be monitored over a longer observation period
compared with the transient availability of human cell subsets
in PBMC-reconstituted animals. Despite these advantages,
however, there are also obvious disadvantages, including the
variability in reconstitution and the genetic heterogeneity among
donors. This may require larger groups of animals to obtain
conclusive results, but in the end might mimic the human situa-
tion more closely. The other point to be considered is that the
human immune system in humanized mice represents a 4- to
6-month-old developmental stage and thus may not fully be
comparable to the immune system of an adult human. This
may explain at least in part some of the differences we observed
with respect to the level of FcgR expression and the overrepre-
sentation of certain cell types, primarily B cells, especially early
after reconstitution.are shown in black, and high-affinity donors (HR-VV, HH-FV, and HH-VV) are
i-CD20 F(ab)2 fragment, and B cell counts were assessed 1 day after antibody
intact 1F5, or aglycosylated 1F5 antibody (PNGaseF). Statistical analysis was
ate values with a significant difference. *p < 0.05, **p < 0.01.
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By studying antibody-dependent B cell depletion in this model
system, we were able to show that the efficacy of target cell
depletion varied greatly depending on the anatomical site.
Thus, whereas mature B cells of the peripheral blood and the
spleen were depleted very effectively even by small antibody
doses, an at least 10-fold higher amount of antibody was
required to deplete mature B cells in the bone marrow. Although
immature B cells expressed only slightly lower levels of CD20
compared with mature B cells and were bound by the same
amount of cytotoxic antibody, they did not become depleted effi-
ciently even at high antibody doses, suggesting that the bone
marrow may represent a niche with low antibody-dependent
cell-mediated cytotoxicity (ADCC) activity. An alternative but
nonmutually exclusive explanation is that immature B cells are
somehow resistant to antibody-mediated depletion. A similar
but less pronounced effect could be observed in amodel system
of anti-CD20-mediated depletion of mouse B cells, in which a
5-fold higher dose was required to deplete immature B cells
effectively, consistent with earlier results (Hamaguchi et al.,
2005). Further along these lines, immature mouse B cells ex-
pressing human CD20 as a transgene showed a similar resis-
tance to anti-CD20-dependent depletion (Gong et al., 2005).
The higher ADCC activity toward mature mouse B cells may be
explained at least in part by themuch higher affinity of themouse
IgG2a antibody subclass for the respective murine activating
FcgRI and FcgRIV, which are responsible for B cell depletion in
the mouse (Biburger et al., 2011; Hamaguchi et al., 2006; Beers
et al., 2010). With respect to earlier B cell subsets, which were
also bound by the CD20 antibody, their much lower expression
of CD20 may explain at least in part their resistance to depletion.
As this was not the case for immature B cells, however, other ex-
planations have to be considered. Apart from antibody availabil-
ity, a lack of effector cells required for B cell killing may have the
same effect on ADCC efficacy. CD16+ NK cells, however, were
abundantly present in the bone marrow. Moreover, CD33/
CD16+ monocytes negative for the early monocyte precursor
markers CD34 and CD117 were present in the bone marrow
and have the capacity to develop into fully functional human
macrophages (Tanaka et al., 2012; Li et al., 2013). It remains
possible, however, that although monocytes express all relevant
activating FcgRs and are involved in ADCC reactions in the
blood, they may not be involved in ADCC reactions in the boneFigure 6. Efficiency of Anti-CD20-Dependent Depletion in Different Tis
(A) Flow-cytometry analysis to identify B cell populations in blood (CD45+C
CD45+CD19+CD10+CD34+IgM; pre B cells: CD45+CD19+CD10+CD34Ig
CD45+CD19+CD10CD34IgM+) of humanized Rag2/gc/FcRg/ mice.
(B–D) Quantification of the indicated B cell subpopulations within human CD45+ c
of anti-CD20 IgG1 or PBS in blood (B), spleen (C), and bone marrow (D) by flow
158F/V genotype of the HSCs used to reconstitute themice was determined. Low-
donors (HR-FV) are shown in black, and high-affinity donors (HR-VV and HH-VV)
analysis was performed by ANOVA. If statistical differences were detected, su
and treated (1 mg, 10 mg, 100 mg) groups. Multiple comparisons were corrected for
*p < 0.05, **p < 0.01 (according to Bonferroni correction of three comparisons).
(E and F) Binding (E) and quantification of the binding (F) of 10 mg A647-labeled ag
spleen, and bone marrow 1 day after application as compared with injection of P
(G) Flow-cytometry analysis of humanized mouse (n = 3) or human (n = 3) bone
expression was compared between CD14high- and CD14low-expressing CD33+ c
See also Figure S3 and Table S3.marrow. Alternatively, macrophages have been implicated as
ADCC effector cells in other tissues, such as the liver (Montalvao
et al., 2013; van der Bij et al., 2010). In the bone marrow of
humanized mice and humans, only very few CD68+ cells could
be detected, which may provide an alternative explanation for
the lower ADCC activity. Since a small level of cell depletion
could be achieved at high antibody doses, it will be interesting
to investigate the capacity of ADCC-enhanced antibodies (e.g.,
lacking branching fucose residues) to efficiently deplete B cells
in the bone marrow.
Thus far, we have not observed a correlation between the
efficacy of B cell depletion in the peripheral blood and spleen
of humanized mice or humans and the presence of high- or
low-affinity FcgRIIA and IIIA alleles, which have been correlated
with a better therapeutic outcome for lymphoma or breast can-
cer patients undergoing antibody therapy (Cartron et al., 2002;
Musolino et al., 2008; Weng et al., 2004; Weng and Levy,
2003). To obtain more informative results, we may need to focus
on larger humanizedmouse colonies that exclusively carry either
the high- or low-affinity allelic variants of FcgRIIIA and FcgRIIA,
respectively, and study B cell depletion especially in the bone
marrow. Altogether, this humanized mouse model should allow
a more detailed understanding of human IgG activity on the
background of a human immune system, and may become a
valuable preclinical test system to validate IgG-based immuno-
logicals. Given the capacity of human myeloid precursor cells
to develop into human osteoclasts, this mouse model may also
be suitable for investigating autoantibody-mediated bone loss
in human serum transfer arthritis models.EXPERIMENTAL PROCEDURES
Mice
C57BL/6 mice were bought from Janvier, and Balb/c-Rag2/gc/ (Rag2/
gc/) mice were provided by Hergen Spits (AMC Amsterdam). FcgRI-defi-
cient mice (FcgRI/) and FcgRIV-deficient mice (FcgRIV/) on the
C57BL/6 background, as well as fcer1g-deficient mice (FcRg/) on the
Balb/c and C57BL/6 backgrounds, were provided by Jeffrey Ravetch
(Rockefeller University) and Mark Hogarth (Burnet Institute). Balb/c-Rag2/
gc/FcRg/ (Rag2/gc/FcRg/) mice were generated by crossing Balb/
c-Rag2/gc/ with Balb/c-FcRg/ animals followed by breeding to a ho-
mozygous deletion for all three respective genes. Mice were kept in the animal
facilities of Friedrich-Alexander-University Erlangen-Nu¨rnberg and Rockefellersues
D19+IgM+), spleen (CD45+CD19+IgM+), and bone marrow (pro B cells:
M; immature B cells: CD45+CD19+CD10+CD34IgM+; mature B cells:
ells in humanized Rag2/gc/FcRg/ animals treatedwith the different amounts
cytometry 1 day after antibody injection. The FcgRIIA-131H/R and FcgRIIIA-
affinity donors (HR-FF, RR-FF, and RR-FV) are depicted in red, medium-affinity
are shown in green. Horizontal lines indicate the statistical median. Statistical
bsequent Mann-Whitney tests were performed to compare untreated (0 mg)
by the Bonferroni method. Asterisks indicate values with significant difference.
n.s., not significant.
lycosylated anti-CD20 IgG1 to the indicated B cell populations in vivo in blood,
BS.
marrow CD33+ cell populations within the hCD45+ population. Human FcgR
ells. Shown is one out of three representative independent experiments.
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University under specific pathogen-free conditions in individually ventilated
cages according to the guidelines of the National Institutes of Health and the
legal requirements of Germany and the United States. Immunodeficient
Rag2/gc/ and Rag2/gc/FcRg/ mice were supplied with acidified drink-
ing water (pH 3.0) to minimize the risk of bacterial infections in these heavily
immunocompromised mouse strains.
Generation of Humanized Mice
Newborn Rag2/gc/FcRg/ mice were irradiated at the indicated doses and
injected intravenously with 50,000–80,000 human HSCs 4–6 hr after irradia-
tion. HSCs were purified from umbilical cord blood with the written consent
of patients and according to the ethical guidelines of the University of Erlan-
gen-Nu¨rnberg and the KlinikumFu¨rth. In brief, PBMCswere isolated by density
centrifugation and CD34+ HSCs were purified using the Direct CD34 Progen-
itor Cell Isolation Kit, human (Miltenyi Biotec) according to the manufacturer’s
instructions. Isolated HSCs were frozen and stored in liquid nitrogen until
further use.
In Vivo Platelet Depletion Assay
The ability of murine activating FcgR to mediate human IgG effector functions
was analyzed by intravenous injection of 10 mg of a humanized anti-platelet
(clone 6A6-hIgG1) in C57BL/6, FcRg/, FcgRI/, and FcgRIV/ mice
(all on the C57BL/6 background), and in Rag2/gc/ and Rag2/gc/FcRg/
mice. As described previously, platelet counts in the peripheral blood of
individual mice were assessed before and 4 hr after 6A6-hIgG1 injection
with the use of an Advia120 Hematology System (Siemens) (Nimmerjahn and
Ravetch, 2005).
Fluorescence-Activated Cell Sorting Analysis
Fluorescence-activated cell sorting (FACS) analysis was conducted with
PBMCs isolated from the peripheral blood of humanized mice and human
cancer patients, with their written consent and according to the ethical
guidelines of the University of Erlangen-Nu¨rnberg, by Ficoll density gradient
centrifugation. For bone marrow and spleen, we prepared single-cell suspen-
sions before proceeding to FACS analysis. The following antibodies were
used for staining of murine PBMCs and FcgRs in C57BL/6, Rag2/gc/,
and Rag2/gc/Fcg/ mice: APC-conjugated B220 (clone RA3-6B6)
PerCP-conjugated B220 (clone RA3-6B6), fluorescein isothiocyanate
(FITC)-conjugated TCRb (clone H57-597), PerCP-Cy5.5-conjugated CD11b
(clone M1/70), PE-conjugated CD16/CD32 (clone 2.4G2), biotin-conjugated
CD45.2 (clone 104), CD64 (clone X54-517.1), PE-Cy7-conjugated CD62L
(clone MEL-14), FITC-conjugated IgD (clone 11-26c.2a), APC-conjugated
GR-1 (clone RB6-8C5), FITC-conjugated Ly6G (clone 1A8), biotinylated
IgM (clone II/41), and PE-conjugated CD43 (clone Ly-48) (all purchased
from BD Pharmingen). APC-H7-conjugated CD45 (clone 30-F11) was
purchased from BioLegend. PE-conjugated CD16 (clone 275003) was pur-
chased from R&D. PE-conjugated Nkp46 (clone 29A1.4) and PE-7-conju-
gated CD19 (clone 1D3) were purchased from eBioscience. The following
antibodies (purchased from BD Pharmingen) were used for staining of human
cells and FcR in humanized Rag2/gc/Fcg/ mice: PerCP-conjugated CD3
(clone UCHT1), FITC-conjugated CD10 (clone HI10a), PerCP-conjugated
CD14 (clone M5E2), FITC-conjugated CD16 (clone 3G8), PE-conjugated
CD16 (clone 3G8), PE-conjugated CD16B (clone CLB-gran11.5), PE-conju-
gated CD19 (clone HIB19), PE-Cy7-conjugated CD19 (clone SJ25C1),
PE-Cy7-conjugated CD33 (clone P67-6), PE-conjugated CD34 (clone
8.G12), PerCP-conjugated CD45 (clone 2D1), APC-conjugated CD45 (clone
HI30), APC-H7-conjugated CD45 (clone 2D1), PE-conjugated CD56
(clone NCAM16.2), FITC-conjugated CD64 (clone 10.1), purified CD66c
(clone B6.2/CD66), PE-conjugated CD68 (clone Y1/82A) PE-conjugated
CD117 (clone 104D2), biotinylated IgD (clone IA6-2), biotinylated IgM (clone
G20-127), and PE-conjugated IgM (clone G20-127). FITC-conjugated CD11c
(clone 3.9) was purchased from eBioscience. Alexa647-conjugated CD32
(clone FUN-2) and PerCP-conjugated CD56 (clone HCD56) were purchased
from BioLegend. PE-conjugated human IgG was purchased from Jackson
ImmunoResearch. APC-Cy7-conjugated streptavidin for detection of
biotinylated primary antibodies was purchased from BD Pharmingen. The
following antibodies were produced in our laboratory: murine Alexa647-con-246 Cell Reports 7, 236–248, April 10, 2014 ª2014 The Authorsjugated FcgRIV (clone 9E9), human biotinylated CD32B (clone 2B6), human
FITC-conjugated CD20 (clone 1F5), and human A647-conjugated CD20
(clone 1F5). FACS staining was generally conducted in the presence of unla-
beled CD16/CD32 antibody (clone 2.4G2; Serotec) as a murine Fc blocking
reagent, except for direct analysis of murine FcgRs. To increase the cell
number of rare cell populations, such as NK cells, in the peripheral blood
of humanized mice, blood from several animals was pooled. Experiments
were acquired on a FACSCantoII (BD) and analyzed using FACSDiva or
FlowJo software.
Cloning and Production of Antibodies
Human anti-CD20 IgG (clone 1F5) switch variants were generated as previ-
ously described (Nimmerjahn and Ravetch, 2005). In brief, total RNA was iso-
lated from the 1F5 hybridoma cell line (obtained from ATCC) and subjected to
50-RACE using the 50RACE System for Rapid Amplification of cDNA ends
(Invitrogen) according to the manufacturer’s instructions. The sequences of
the specific primers were as follows: 50-gac agg gat cca gag tt-30 (IgG2a
heavy-chain gene-specific primer 1), 50-gta ctc tag agg tca agg tca ctg gct
ca-30 (IgG2a heavy-chain gene-specific primer 2), 50-cct gtt gaa gct ctt gac
a-30 (k light-chain gene-specific primer 1), and 50-gta ctc tag agg gtg aag ttg
atg tct tgt c-30 (k light-chain gene-specific primer 2). The light- and heavy-chain
variable regions were cloned in pCR-Topo-Blunt (Invitrogen) and confirmed by
sequencing. Primers for PCR amplification of variable regions and subsequent
cloning were derived from the resulting sequence information: 50-cgt aga att
cac cac cat ggg atg gag ttg tat cat c-30 (1F5 VH) and 50-cgt aga att cac cac
cat gga ttt tca agt gca gat tt-30 (1F5 VL). The heavy-chain variable region
was fused to heavy-chain constant regions of the human IgG subclasses
and cloned into the eukaryotic pBos expression vector via EcoRI and KpnI re-
striction sites. The kappa light-chain variable region was fused to the human
kappa light-chain constant region and cloned in the pCMV vector via NcoI
and XhoI restriction sites. Antibodies were produced by transient transfection
in HEK293T cells and subsequent isolation from the cell culture supernatant by
ammonium sulfate precipitation and protein G purification as previously
described (Nimmerjahn and Ravetch, 2005). The integrity of the produced
switch variants was confirmed by reducing PAGE. The F(ab)2 fragment of
the antibody was generated by digestion with pepsin for 2 hr at 37C in a buffer
of 0.1 M sodium citrate (pH 3.5) followed by dialysis against PBS. Deglycosy-
lation of anti-CD20 IgG was achieved by digestion with 50 U/mg PNGase F
overnight at 37C.
Anti-CD20 IgG-Induced B Cell Depletion In Vivo
Anti-CD20 IgG switch variants were intravenously injected into 12- to 16-
week-old humanized Rag2/gc/FcRg/ mice at the indicated amounts. B
cell counts in peripheral blood were analyzed by flow cytometry before and
1 and 7 days after antibody injection. B cell counts in spleen and bone marrow
were analyzed 1 day after antibody application.
ELISA-Based Assays
Serum of humanized Rag2/gc/FcRg/ mice was analyzed for the presence
of humanC3 protein by a sandwich ELISA using goat human antibody comple-
ment C3 F(ab)2 fragment (Cappel) as the capture antibody and peroxi-
dase-conjugated goat IgG fraction to human complement C3 (Cappel) as
the detection antibody. For comparison, human serum and C57BL/6 serum
were used as positive and negative controls, respectively. For quantification
of total serum IgM and IgG in humanized mice, the Bethyl Human IgM ELISA
Quantitation Kit and the Human IgG ELISA Quantitation Kit (Biomol) were
used according to the manufacturer’s instructions. Optical density was
measured with a VersaMax tunable microplate reader (Molecular Devices) at
450 and 650 nm.
Isolation of Genomic DNA and Genotyping
Human FcgRIIA-131H/R and FcgRIIIA-158F/V polymorphisms were deter-
mined as previously described (Baerenwaldt et al., 2011). In brief, 250 ml of
umbilical cord blood samples was taken and stored at 20C before HSCs
were isolated. Genomic DNA was isolated with the QiaAmp DSP Blood Mini
Kit (QIAGEN) following the instructions of the distributor. To identify the
FcgRIIA-131H/R and FcgRIIIA-158F/V allelic variants, allele-specific nested
PCRs were performed as previously described (Baerenwaldt et al., 2011).
Osteoclast Differentiation
Total single-cell bone marrow preparations of humanized Rag2/gc/FcRg/
mice or human peripheral blood (after red blood cell lysis) were cultured
overnight with 30 ng/ml of human M-CSF. For osteoclast differentiation, the
nonadherent cells were cultured further in a-MEM supplemented with 10%
heat-inactivated fetal calf serum, glutamine, penicillin, and streptomycin (all
from Invitrogen); 30 ng/ml human M-CSF; and 50 ng/ml hRANKL (PeproTech).
After 14 days of culture, the cells were stained for TRAP by using Leukocyte
Acid Phosphatase Kit 386A (Sigma-Aldrich) to identify osteoclasts. To deter-
mine osteoclast activity, the OsteoLyse Assay Kit (Lonza) was used according
to the manufacturer’s instructions. In brief, 100,000 nonadherent cells were
seeded and after 7 days under osteoclast differentiation conditions, the
supernatant was collected. The released fluorescence in the medium was
measured using a time-resolved fluorescence fluorimeter (Wallac Victor3;
PerkinElmer).
Statistics
The statistical significance of the data was determined as indicated in the
figure legends. In brief, the Mann-Whitney test or Wilcoxon signed rank test
was applied to compare two experimental groups, and the Kruskal-Wallis
test or ANOVA (and subsequent post hoc tests or Mann-Whitney test and
Bonferroni correction) were used to determine statistical differences between
more than two groups. To indicate different levels of significance, a p value of
0.05 was assigned one asterisk, and a value smaller than 0.05 but larger than
0.001 was assigned two asterisks.
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